Evidence map›Paper›PMID 30439567›Full record

ArticleNeoplasia (New York, N.Y.)2018

Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.

Chinnadurai Mani, Sachin Pai, Cinta Maria Papke, Komaraiah Palle, William H Gmeiner

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Chinnadurai ManiDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604.
Sachin PaiDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604.
Cinta Maria PapkeDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604.
Komaraiah PalleDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604. Electronic address: komaraiah.palle@ttuhsc.edu.
William H GmeinerDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157. Electronic address: bgmeiner@wakehealth.edu.
University of South Alabama · USUSA Mitchell Cancer Institute · USWake Forest University · US

Funding

Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrenceR01CA219187 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PALLE, KOMARAIAH · 2018 to 2023
$2.6M
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecinR01GM098956 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PALLE, KOMARAIAH · 2012 to 2016
$1.1M
Development of a CF10 Predictive Gene Signature in CRC Organoids.R21CA218933 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GMEINER, WILLIAM H. · 2018 to 2019
$366k
NCI NIH HHS R01 CA219187NCI NIH HHS R21 CA218933NIGMS NIH HHS R01 GM098956
6 · The paper itself

Abstract

We are developing the fluoropyrimidine polymer F10 to overcome limitations of 5-fluorouracil (5-FU) that result from inefficient metabolism to 5-fluoro-2'-deoxyuridine-5'-mono- and tri-phosphate, the deoxyribonucleotide metabolites that are responsible for 5-FU's anticancer activity. F10 is much more cytotoxic than 5-FU to colorectal cancer (CRC) cells; however, the mechanism of enhanced F10 cytotoxicity remains incompletely characterized. Using DNA fiber analysis, we establish that F10 decreases replication fork velocity and causes replication fork collapse, while 1000-fold excess of 5-FU is required to achieve similar endpoints. Treatment of HCT-116 cells with F10 results in Chk1 phosphorylation and activation of intra-S-phase checkpoint. Combining F10 with pharmacological inhibition of Chk1 with either PF-477736 or prexasertib in CRC cells enhanced DNA damage relative to single-agent treatment as assessed by γH2AX intensity and COMET assay. PF-477736 or prexasertib co-treatment also inhibited upregulation of Rad51 levels in response to F10, resulting in reduced homologous repair. siRNA knockdown of Chk1 also increased F10-induced DNA damage assessed and sensitized CRC cells to F10. However, Chk1 knockdown did not inhibit Rad51 upregulation by F10, indicating that the scaffolding activity of Chk1 imparts activity in DNA repair distinct from Chk1 enzymatic activity. Our results indicate that F10 is cytotoxic to CRC cells in part through DNA damage subsequent to replication fork collapse. F10 is ~1000-fold more potent than 5-FU at inducing replication-mediated DNA damage which correlates with the increased overall potency of F10 relative to 5-FU. F10 efficacy can be enhanced by pharmacological inhibition of Chk1.

Indexed as

Cell Line, TumorCheckpoint Kinase 1DNA DamageDNA ReplicationDrug SynergismFluorodeoxyuridylateGene Knockdown TechniquesHumansProtein Kinase InhibitorsS Phase Cell Cycle CheckpointsStress, PhysiologicalCheckpoint Kinase 1FdUMP(10)FluorodeoxyuridylateProtein Kinase Inhibitors

Identifiers

PMID30439567
PMCPMC6232621
OpenAlexW2901618658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.